Dublin, Dec. 03, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/sf3m94/cell_therapy) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.
This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.
Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.
Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.
The cell-based markets was analyzed for 2014, and projected to 2024.The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.
The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 300 of these are profiled in part II of the report along with tabulation of 287 alliances. Of these companies, 168 are involved in stem cells. Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 62 Tables and 18 Figures. The bibliography contains 1,200 selected references, which are cited in the text.
Key Topics Covered:
Executive Summary
1. Introduction to Cell Therapy
2. Cell Therapy Technologies
3. Stem Cells
4. Clinical Applications of Cell Therapy
5. Cell Therapy for Cardiovascular Disorders
6. Cell Therapy for Cancer
7. Cell Therapy for Neurological Disorders
8. Ethical, Legal and Political Aspects of Cell therapy
9. Safety and Regulatory Aspects of Cell Therapy
10. Markets and Future Prospects for Cell Therapy
11. Companies Involved in Cell Therapy
12. Academic Institutions
13. References
For more information visit http://www.researchandmarkets.com/research/sf3m94/cell_therapy
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Genomics


Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 



